📰 ReutersReutersCodex · 实盘不做把握 7/10
北京时间·🕒 发布 07-30 18:04:11时区推断·⟳ 抓取 07-30 18:04:43·⚡ 决策 07-31 01:56:16 +7h51m·88.7 天前
信诺集团二季度业绩小幅超预期并上调全年利润指引
信诺集团（CI.US）二季度调整后EPS为7.78美元，高于7.60美元预期，收入716.7亿美元也高于703.4亿美元预期。
📄 原文Reuters↗ 原文
Cigna (CI.N) on Thursday raised its annual profit forecast, after beating quarterly earnings estimates on growth in its…
不做 信诺集团（CI.US）
财报正向但预期差太薄：全年EPS指引30.45美元仅略高于30.41美元一致预期，PBM利润承压且股价盘中已跌约2%，不追多；净事件又不是强空催化，不做空。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 公司当天发布二季度财报，确认收入增长7%、调整后EPS为7.78美元，并将2026年调整后EPS指引上调至至少30.45美元。
- Reuters在美股盘前报道信诺上调全年利润预测，正文同时指出MLR略高于去年且接近分析师预期。
- Barron's指出业绩 beat 但指引基本贴近市场预期，且PBM利润下滑拖累股价表现。市场反应:报道时称CI股价下跌约2.5%。
- 2026-07-30 13:54 ET市场反应stock_quote非一手行情显示信诺集团（CI.US）报289.99美元，较前收296.47美元下跌2.19%。市场反应:盘中下跌2.19%，未确认正向追多edge。
关键理由
- 信诺集团（CI.US）二季度调整后EPS为7.78美元，高于7.60美元预期，收入716.7亿美元也高于703.4亿美元预期。
- 全年调整后EPS指引仅从至少30.35美元上调至30.45美元，较LSEG一致预期30.41美元只高约0.1%，正向预期差很薄。
- Evernorth收入增长但PBM税前调整经营利润同比下降27%，叠加股价盘中下跌约2%，说明市场没有按强利好重定价。
主要风险
- 这是预定财报日事件，业绩和指引更新已在美股盘中交易数小时，剩余可交易edge不足。
- 若后续电话会给出超预期回购、成本趋势改善或PBM利润修复指引，需由新信号重新研判。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-07-30 · 影响 weakens
反向证据显示全年EPS指引几乎贴近一致预期，PBM税前调整经营利润同比下降27%，削弱追多理由。
检索:Cigna Q2 2026 guidance meets expectations PBM operating income decline stock drops 原文 ↗ - 做空前查反向 · 来源 filing · 日期 2026-07-30 · 影响 weakens
公司仍实现收入和EPS beat并上调全年利润指引，当前事件不是明确强空催化。
检索:The Cigna Group Q2 2026 earnings release raised outlook adjusted EPS 30.45 原文 ↗ - 做多前查反向 · 来源 kb_search · 影响 none
内部KB检索实际调用但服务超时，未用于提高做多置信度。
检索:Cigna 2026 Q2 earnings guidance Evernorth medical loss ratio consensus
工具调用 · 历史记录,结果未知(2 种)
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 1,948 字
Cigna (CI.N) on Thursday raised its annual profit forecast, after beating quarterly earnings estimates on growth in its pharmacy and specialty drug businesses.
The company has been reducing its exposure to government-backed health insurance businesses due to elevated medical costs, exiting Medicare Advantage last year and announcing it will stop offering plans under the Affordable Care Act, or Obamacare, at the end of 2026.
Instead, it has shifted focus toward its core traditional employer-sponsored healthcare business and its pharmacy benefits management unit.
Second-quarter adjusted revenue at its Evernorth Health Services unit - which includes the pharmacy benefit management unit and specialty pharmacy - rose 6% to $61.47 billion.
Growth in the segment was partly boosted by higher use of specialty drugs for complex conditions such as cancer, multiple sclerosis and rheumatoid arthritis, the company said.
Pharmacy benefit managers help negotiate drug prices and coverage with manufacturers on behalf of employers and health plan clients.
The company's medical loss ratio, or the percentage of premiums spent on medical care, stood at 84.5% for the quarter, higher than 83.2% last year. Analysts were expecting a medical loss ratio of 84.46%, according to data compiled by LSEG.
The prior-year quarter had benefited from higher risk-adjustment payments in its individual and family plans business, Cigna said. Those payments compensate insurers that cover a disproportionate share of sicker members.
The company raised its 2026 adjusted profit forecast by 10 cents to at least $30.45 per share. Analysts, on average, estimate the company's annual earnings at $30.41 per share.
On an adjusted basis, the company earned $7.78 per share in the second quarter, beating estimates of $7.60 per share.
Total revenue for the quarter rose 7% to $71.67 billion, compared with analysts' estimates of $70.34 billion.
The company has been reducing its exposure to government-backed health insurance businesses due to elevated medical costs, exiting Medicare Advantage last year and announcing it will stop offering plans under the Affordable Care Act, or Obamacare, at the end of 2026.
Instead, it has shifted focus toward its core traditional employer-sponsored healthcare business and its pharmacy benefits management unit.
Second-quarter adjusted revenue at its Evernorth Health Services unit - which includes the pharmacy benefit management unit and specialty pharmacy - rose 6% to $61.47 billion.
Growth in the segment was partly boosted by higher use of specialty drugs for complex conditions such as cancer, multiple sclerosis and rheumatoid arthritis, the company said.
Pharmacy benefit managers help negotiate drug prices and coverage with manufacturers on behalf of employers and health plan clients.
The company's medical loss ratio, or the percentage of premiums spent on medical care, stood at 84.5% for the quarter, higher than 83.2% last year. Analysts were expecting a medical loss ratio of 84.46%, according to data compiled by LSEG.
The prior-year quarter had benefited from higher risk-adjustment payments in its individual and family plans business, Cigna said. Those payments compensate insurers that cover a disproportionate share of sicker members.
The company raised its 2026 adjusted profit forecast by 10 cents to at least $30.45 per share. Analysts, on average, estimate the company's annual earnings at $30.41 per share.
On an adjusted basis, the company earned $7.78 per share in the second quarter, beating estimates of $7.60 per share.
Total revenue for the quarter rose 7% to $71.67 billion, compared with analysts' estimates of $70.34 billion.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。